Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q3 2014 · 10-Q
Revenue—
Net Income-$3.45M-$3.45MN/M vs Q3 2013 EPS Diluted-$0.17-$0.17N/M vs Q3 2013 Operating Income-$3,453,000N/M Operating Cash Flowderived-$3,378,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Sep 30, 2014 · filed Nov 13, 2014 · 44 d after period end